LATEST NEWS

Category Archives: HSD

Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital III Partners (Vesalius III). This is in addition to the €12 million Series A financing in 2014 and €5,7 million R&D loans granted by Business […]

Forendo receives clinical trial authorization to initiate phase I study

Forendo Pharma has received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study for its lead program, FOR-6219. Endometriosis is a chronic condition that affects up to 10% of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available […]

Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the chairperson

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act […]

Meet us in San Francisco during Biotech Showcase 2016

Forendo Pharma will be in San Francisco, California, for meetings with partners during Biotech Showcase and JP Morgan conference, from January 11th to 13th 2016. Biotech Showcase is the leading investor conference for mid-small cap and private biotech and life science companies. Our company presentation will be on Monday, January 11th, at 3:30 pm. Please contact […]

The most comprehensive overview of the proteome profile in the ovarian endometriosis

New molecular information on potential therapeutic targets or tools for non-invasive diagnosis for endometriosis, are important for patient care and treatment. Whilst much work has been dedicated establishing genomic profiles, only few efforts have carried out at the protein level. Forendo’s academic collaborators from the University of Turku have been in major role in a […]

Categories: HSD

New drug candidate showed efficacy in human endometriosis samples

Our collaborators from the University of Maastricht have published the study titled: “Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions.” In this study Andrea Romano and his team studied the efficacy of Forendo’s new drug candidate in human endometriosis samples. The results showed that the expression of HSD17B1 enzyme, […]

Categories: HSD